Critical Survey: NanoVibronix (NASDAQ:NAOV) vs. Anteris Technologies Global (NASDAQ:AVR)

Anteris Technologies Global (NASDAQ:AVR) and NanoVibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Profitability

This table compares Anteris Technologies Global and NanoVibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	N/A	N/A	N/A
NanoVibronix	-93.80%	-101.17%	-53.03%

Insider & Institutional Ownership

16.4% of NanoVibronix shares are owned by institutional investors. 7.0% of NanoVibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Anteris Technologies Global and NanoVibronix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	0	0	4	0	3.00
NanoVibronix	0	0	0	0	0.00

Anteris Technologies Global presently has a consensus price target of $16.50, indicating a potential upside of 412.42%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, research analysts plainly believe Anteris Technologies Global is more favorable than NanoVibronix.

Valuation and Earnings

This table compares Anteris Technologies Global and NanoVibronix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$2.71 million	42.79	N/A	N/A	N/A
NanoVibronix	$3.29 million	0.57	-$3.71 million	($13.53)	-0.17

Anteris Technologies Global has higher earnings, but lower revenue than NanoVibronix.

Summary

Anteris Technologies Global beats NanoVibronix on 7 of the 10 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

About NanoVibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.